Clinical trials: Proton Pump Inhibitors
Gastroesophageal Reflux Disease, Systemic Sclerosis
Gastroesophageal Reflux Treatment in Scleroderma
The investigators purposes are to define the prevalence of omeprazole resistance gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc), to compare the efficacy of omeprazole in combination with algycon versus…
- Conditions
- Gastroesophageal Reflux Disease, Systemic Sclerosis, Scleroderma
- Trial name
- GERD-SSc (NCT01878526)
- Testing
- Alginic acid, Domperidone
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Khon Kaen University
Cirrhosis, Healthy
Proton Pump Inhibitors and Dysbiosis in Cirrhosis
The purpose of this study is to find out whether the use of medications that suppress acid in your stomach can change the composition of your bowel bacteria.
- Trial name
- NCT01458990
- Testing
- Omeprazole
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Gastroesophageal Reflux Disease
An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Refractory GERD Patients
The purpose of this trial is to investigate the pharmacodynamic effect on reflux parameters of SPD557 tablets (0.5 mg t.i.d., on top of PPI treatment) in patients with Gastroesophageal Reflux Disease (GERD) with persistent…
- Trial name
- NCT01370863
- Testing
- SPD557
- Where
- 15 sites in Belgium, France and 4 more
- Volunteers
- 67 people
- Sponsor
- Shire
Healthy Volunteers
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
The purpose of this study is to determine if taking Vyvanse with Prilosec OTC or Adderall XR with Prilosec OTC changes how quickly the drug is absorbed into the body and/or changes how much of the drug is absorbed into the body.
- Trial name
- NCT00746733
- Testing
- Lisdexamfetamine Dimesylate, Adderall XR (mixed salts amphetamine)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shire
Gastroesophageal Reflux Disease (GERD)
The EndoGastric Solutions TEMPO Trial
The purpose of this study is to assess the efficacy and safety of Transoral Incisionless Fundoplication (TIF) performed with EsophyX as compared to proton pump inhibitor (PPI) therapy for the treatment of chronic Gastroesophageal…
- Trial name
- TEMPO (NCT01647958)
- Testing
- EsophyX System with SerosaFuse fasteners, PPI
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- EndoGastric Solutions
Peptic Ulcer
Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers
Whether pantoprazole versus famotidine for the prevention of recurrent peptic ulcers in thienopyridine users remains unclear.
- Trial name
- NCT02551744
- Testing
- histamine-2 receptor antagonist group, proton pump inhibitor group
- Where
- Taiwan
- Volunteers
- 101 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Healthy
A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)
The purpose of this study is to compare the pharmacodynamics/pharmacokinetics of 5 mg, 10 mg, 20 mg and 40 mg of Rabeprazole sodium (E3810) when administered repeatedly once daily for 5 days to healthy adult male Japanese…
- Trial name
- NCT01202071
- Testing
- Rabeprazole sodium, 5 mg Tablets, Rabeprazole sodium, 10 mg Tablets, Rabeprazole sodium, 20 mg Tablets
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eisai Co., Ltd.
Cystic Fibrosis
Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations
Gastroesophageal reflux disease (GERD) is a common problem in cystic fibrosis (CF). It may lead to worsening lung function and more respiratory infections for a person with CF.
- Trial name
- NCT01983774
- Testing
- Esomeprazole
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Columbia University
Healthy
A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations
Relative bioavailability study to evaluate the pharmacokinetics of two new encorafenib formulations
- Trial name
- ERBA (NCT05446142)
- Testing
- Encorafenib capsule formulation (CAP), Encorafenib first formulation, Encorafenib second formulation
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Clostridium Difficile
Effects of Gastric Acid on Colonic Microbiome
The colonic microbiome is essential in human health and disease. Clostridium difficile-associated diarrhea (CDAD), a highly morbid form of infectious diarrhea, is caused by antibiotics which perturb the microbiome and allow C.
- Trial name
- NCT01901276
- Testing
- Omeprazole 40 mg bid
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Daniel Freedberg, MD
Erosive Esophagitis
A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
This study will be conducted in patients with erosive esophagitis due to gastro-esophageal reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial symptom response but still endoscopically…
- Trial name
- NCT05055128
- Testing
- X842, X842 Dummy, Lansoprazole
- Where
- 42 sites in United States, Bulgaria and 6 more
- Volunteers
- 248 people
- Sponsor
- Cinclus Pharma Holding AB
Gastro Oesophageal Reflux Disease
Study Comparing Fexuprazan and Esomeprazole in Patients With Gastroesophageal Reflux Disease
The goal of this clinical trial was to evaluate the effectiveness and safety of fexuprazan 40 mg for relieving symptoms of gastroesophageal reflux disease (GERD) in adults.
- Trial name
- NCT07326904
- Testing
- Fexuprazan, Esomeprazole
- Where
- 3 sites in Indonesia
- Volunteers
- 145 people
- Sponsor
- Universitas Indonesia
Healthy Volunteers
Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets
The purpose of this study is to measure the amount of study drug present in blood after being administered a generic version of nifedipine extended-release tablets, 60 mg (Valeant Pharmaceuticals, LLC) and brand-name version…
- Trial name
- NCT03100838
- Testing
- Nifedipine 60 MG Extended Release Oral Tablet, omeprazole/sodium bicarbonate, SmartPill (TM)
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Food and Drug Administration (FDA)
Gastroesophageal Reflux
Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy
The purpose of this study is to determine if patients with well-controlled heartburn symptoms on twice-daily proton pump inhibitor therapy remain well-controlled after stepping down to once-daily (QD) dexlansoprazole modified…
- Trial name
- NCT00847808
- Testing
- Dexlansoprazole MR QD
- Where
- 52 sites in United States
- Volunteers
- 178 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease, Eosinophilic Esophagitis
The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors
Background: Up to 40% of patients who are treated with PPIs for symptoms that are thought to be due to GERD experience only incomplete relief of their symptoms.
- Trial name
- NCT01404832
- Testing
- Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Dallas VA Medical Center
Hypothyroidism;Postablative
Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
This is an open-label therapeutic efficacy study of Tirosint (levothyroxine sodium) capsules in thyroidectomized patients taking proton pump inhibitors and levothyroxine, evaluating changes in serum levels of Thyroid Stimulating…
- Trial name
- NCT03094416
- Testing
- levothyroxine sodium capsule, Proton pump inhibitor (PPI), Levothyroxine Sodium (LT4) Tablets
- Where
- 9 sites in United States
- Volunteers
- 66 people
- Sponsor
- IBSA Institut Biochimique SA
Gastroesophageal Reflux Disease (GERD)
Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD)…
- Trial name
- NCT03561883
- Testing
- IW-3718, Standard-dose PPIs QD
- Where
- 101 sites in United States, Canada
- Volunteers
- 609 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Non-erosive Gastroesophageal Reflux Disease
A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease
To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal reflux disease in a multicenter, randomized, double-blind…
- Trial name
- NCT00165646
- Testing
- E3810
- Where
- 35 sites in Japan
- Volunteers
- 288 people
- Sponsor
- Eisai Co., Ltd.
Liver Cirrhosis, Hypertension, Portal
PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)
This study is aimed at investigating the effect of PPIs on gastroesophageal varices in liver cirrhosis. Half of participants will receive PPI, while the other half will receive a placebo.
- Trial name
- PPIs (NCT03175731)
- Testing
- Proton Pump Inhibitors
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Yanjing Gao
Upper Gastrointestinal Bleeding
Anticoagulation With Enhanced Gastrointestinal Safety (AEGIS) Trial
This is a pragmatic, single center, feasibility pilot cluster randomized trial with embedded individual randomization to evaluate implementation strategies to increase the use of evidence-based practices to reduce upper…
- Trial name
- AEGIS (NCT05085405)
- Testing
- Clinician notification, Clinician Notification with Nurse Facilitation, Clinician Notification / Patient Activation
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Michigan